Aerska

Aerska develops RNA-based medicines designed to treat, delay, and prevent diseases of the brain by targeting harmful genes through RNA interference and delivering these therapies into the central nervous system using specialised delivery methods. The company focuses on overcoming biological barriers that typically block genetic medicines from reaching the brain, supporting systemic administration and neuronal uptake to modulate disease drivers. It integrates data-driven approaches to align therapeutic development with patient biology across neurological conditions like Alzheimer’s and Parkinson’s. Aerska combines expertise in RNA chemistry, precision delivery technologies, and translational strategies to advance its therapeutic programmes toward clinical evaluation.

Domain

aerska.com

Country

Ireland

Employees

11-50

Last Funding

$39.0M

Founded

2024

Frequently Asked Questions

What technologies does Aerska use?+

Aerska uses 15 technologies including Cookiebot, Google Tag Manager, Webflow.

What industry is Aerska in?+

Aerska operates in the Biotechnology industry.

Where is Aerska based?+

Aerska is headquartered in Ireland.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026